Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory
about
Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyLongitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage TherapyHIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, ChinaComparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical TransmissionSensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.High-Throughput Sequencing, a VersatileWeapon to Support Genome-Based Diagnosis in Infectious Diseases: Applications to Clinical BacteriologyA general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library.Clinical implications of HIV-1 minority variantsLow-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.Deep sequencing: becoming a critical tool in clinical virology.Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
P2860
Q28537608-7513ACD3-C14D-4B6E-B574-BB3C0735294FQ28541754-3555E1A7-5A7D-40AA-A567-1AE415E9D924Q28547874-67FFB8B1-1AB1-4EB7-9B2E-8DA886FE7DB5Q28550283-23405272-C40D-468D-9196-EF1F206179BFQ28550310-3B2A3B18-794A-418A-B6CD-75AD91032A6AQ33622927-8ADBACC5-B31E-4560-A46A-68D1DBB7EE71Q34569184-EDA7F0F2-B0FB-4478-8A8E-DA912599CD56Q35494993-C1690A7A-47BC-46F1-88E3-4135874C5777Q36811249-069A983B-69EC-4D25-BD05-BD9BD45586B4Q36933330-F905B71A-46A4-442E-9BE8-B0FB9E430BE0Q38226696-81596A10-6720-47E4-BC87-B819711D52E7Q38383070-7A71792D-1EC3-4A9B-85A2-35D77FBD7EA9Q55511989-9727F228-A697-4F72-BBCA-894CA5A2D477
P2860
Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@ast
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@en
type
label
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@ast
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@en
prefLabel
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@ast
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@en
P2093
P2860
P356
P1476
Evaluation of a benchtop HIV u ...... say in the clinical laboratory
@en
P2093
Boaz Avidor
Dan Turner
Danny Alon
David Hassin
Eugene Katchman
Hadass Talio
Ilana S Fratty
Ina Vulih Shultsman
Irene Zeldis
Israel Yust
P2860
P304
P356
10.1128/JCM.02652-12
P407
P577
2013-01-02T00:00:00Z